PDCD1 and neoplasm: In the E0771 cohort, mice receiving the combination treatment of anti-PD-1 and carbo/pax had the lowest tumor burden, with significant decreases compared to the carbo/pax (p = 0.0062) and IgG isotype control groups (p = 0.0386) (Fig. 8B).